Figure 6

BDNF priming counteracts inhibitory MAG-effects on β1-integrin clustering and growth inhibition. (A) Representative immunolabeled images showing β1-integrin after control (BSA), MAG (1 μg/mL; 5 min), or combination treatments with BDNF (50 ng/mL; 20 min) and MAG. Detailed time course graphical representation of the combination treatments located in Additional file 8. Arrowheads designate clustered β1-integrins. Scale bar, 5 μm. (B) Quantification of β1-integrin clustering after vehicle (BSA), BDNF (50 ng/mL), and MAG (1 μg/mL) treatments alone or followed by secondary exposure to BDNF or MAG. (C) Quantification of β1-integrin surface levels after vehicle (BSA), BDNF (50 ng/mL), and MAG (1 μg/mL) treatments alone or followed by secondary exposure to BDNF or MAG. (D) Quantification of the mean axon growth rate according to the treatment groups. Data are the mean ± standard error of the mean. (n > 150, *P < 0.01, **P < 0.001, ANOVA with Tukey's post hoc analysis.) BDNF: brain-derived neurotrophic factor; BSA: bovine serum albumin; MAG: myelin-associated glycoprotein.